DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
DREADD agonist 21 (Compound 21) (HB4888)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant.
Purity:>98%
-
(S)-Duloxetine hydrochloride (HB1806)
Description:Potent 5-HT and NA reuptake inhibitor. Also inhibits dopamine reuptake.
Purity:>99%
-
DY131 (HB2491)
Description:Novel selective estrogen-related receptor ERRβ and ERRγ agonist
Purity:>99%
-
-
-
-
1-EBIO (HB1045)
Description:Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.
Purity:>98%
-
-
EC 23 (HB2592)
Description:Synthetic retinoid. Induces neural differentiation of hESCs.
Purity:>99%
